January 4, 2021 – Philadelphia, PA – We are pleased to announce that Dr. Angela Chen will be joining WuXi Advanced Therapies Unit (WuXi ATU), as General Manager of WuXi ATU in China and Asian Commercial Head.
Dr. Angela Chen brings strong leadership and a wealth of experience in gene and cell therapy research, Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) industry commercial and business development. Before she joined WuXi ATU, she was CEO of Porton Biologics Ltd. Prior to Porton, Dr. Angela Chen was the Global Strategy and Commercial Leader, Enterprise Solution of Cell and Gene Therapy at Cytiva (formally GE HealthCare Life Sciences) based in Marlborough, MA (2019-2020), and she was previously the Business Leader of GE HealthCare Life Sciences Cell and Gene Therapy, Asia (2017-2019) and China (2015-2017) based in Shanghai.
Earlier in her career, Dr. Angela Chen worked at Sigma Aldrich as the Director of Sales & Marketing in Shanghai. She was also formerly the head of Business Development & PM at HD Biosciences Co., Ltd. (later became part of WuXi AppTec) in Shanghai, and the Product Manager of Genotyping at Rosetta Biosoftware in Seattle, WA. Dr. Angela Chen has a B.S. degree in Biochemisty from Fudan University, Ph.D. in Human Genetics from University of Pittsburgh, and MBA from University of Pittsburgh Katz Graduate School of Business.
We are excited to welcome Dr. Chen to WuXi Advanced Therapies!
About WuXi Advanced Therapies (ATU)
As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the development, testing, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals. Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit www.advancedtherapies.com
Global Head of Marketing
WuXi Advanced Therapies